company background image
SELB

Selecta Biosciences NasdaqGM:SELB Stock Report

Last Price

US$1.84

Market Cap

US$281.6m

7D

3.4%

1Y

-18.6%

Updated

04 Feb, 2023

Data

Company Financials +

Selecta Biosciences, Inc.

NasdaqGM:SELB Stock Report

Mkt Cap: US$281.6m

SELB Stock Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

SELB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Selecta Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Selecta Biosciences
Historical stock prices
Current Share PriceUS$1.84
52 Week HighUS$2.73
52 Week LowUS$0.65
Beta0.98
1 Month Change58.62%
3 Month Change12.20%
1 Year Change-18.58%
3 Year Change-59.29%
5 Year Change-78.33%
Change since IPO-86.86%

Recent News & Updates

Recent updates

We Think Selecta Biosciences (NASDAQ:SELB) Can Stay On Top Of Its Debt

Sep 23
We Think Selecta Biosciences (NASDAQ:SELB) Can Stay On Top Of Its Debt

Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape

Aug 15

Selecta Biosciences Q2 2022 Earnings Preview

Aug 03

Selecta: Not For The Faint Of Heart

May 16

Selecta Biosciences (NASDAQ:SELB) Has Debt But No Earnings; Should You Worry?

Mar 30
Selecta Biosciences (NASDAQ:SELB) Has Debt But No Earnings; Should You Worry?

Circling Back On Selecta Biosciences

Dec 20

Upgrade: Analysts Just Made A Stunning Increase To Their Selecta Biosciences, Inc. (NASDAQ:SELB) Forecasts

Aug 14
Upgrade: Analysts Just Made A Stunning Increase To Their Selecta Biosciences, Inc. (NASDAQ:SELB) Forecasts

Selecta Biosciences Has Multiple Shots On Goal

Jun 28

Analysts' Revenue Estimates For Selecta Biosciences, Inc. (NASDAQ:SELB) Are Surging Higher

Jun 22
Analysts' Revenue Estimates For Selecta Biosciences, Inc. (NASDAQ:SELB) Are Surging Higher

Shareholders May Be A Bit More Conservative With Selecta Biosciences, Inc.'s (NASDAQ:SELB) CEO Compensation For Now

Jun 12
Shareholders May Be A Bit More Conservative With Selecta Biosciences, Inc.'s (NASDAQ:SELB) CEO Compensation For Now

Time To Worry? Analysts Are Downgrading Their Selecta Biosciences, Inc. (NASDAQ:SELB) Outlook

May 16
Time To Worry? Analysts Are Downgrading Their Selecta Biosciences, Inc. (NASDAQ:SELB) Outlook

Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Are Pretty Bullish On The Stock After Recent Results

Mar 13
Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Are Pretty Bullish On The Stock After Recent Results

How Much Did Selecta Biosciences'(NASDAQ:SELB) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19
How Much Did Selecta Biosciences'(NASDAQ:SELB) Shareholders Earn From Share Price Movements Over The Last Three Years?

Selecta announces preclinical data to validate its therapeutic platform

Jan 06

Selecta: ImmTOR Platform's Potential In Key

Dec 25

Insider Buying: The Selecta Biosciences, Inc. (NASDAQ:SELB) Chief Medical Officer Just Bought US$129k Worth Of Shares

Dec 22
Insider Buying: The Selecta Biosciences, Inc. (NASDAQ:SELB) Chief Medical Officer Just Bought US$129k Worth Of Shares

Selecta Biosciences CMO buys over $120K shares, stock +10% AH

Dec 16

Is Selecta Biosciences, Inc. (NASDAQ:SELB) Popular Amongst Insiders?

Dec 14
Is Selecta Biosciences, Inc. (NASDAQ:SELB) Popular Amongst Insiders?

Selecta's gene therapy gets Orphan Drug tag for rare metabolic disorder

Nov 19

Shareholder Returns

SELBUS BiotechsUS Market
7D3.4%-0.8%1.7%
1Y-18.6%4.4%-9.6%

Return vs Industry: SELB underperformed the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: SELB underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is SELB's price volatile compared to industry and market?
SELB volatility
SELB Average Weekly Movement10.1%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: SELB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: SELB's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200758Carsten Brunnhttps://selectabio.com

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura.

Selecta Biosciences, Inc. Fundamentals Summary

How do Selecta Biosciences's earnings and revenue compare to its market cap?
SELB fundamental statistics
Market CapUS$281.58m
Earnings (TTM)US$41.73m
Revenue (TTM)US$123.92m

6.7x

P/E Ratio

2.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SELB income statement (TTM)
RevenueUS$123.92m
Cost of RevenueUS$73.73m
Gross ProfitUS$50.19m
Other ExpensesUS$8.47m
EarningsUS$41.73m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.27
Gross Margin40.50%
Net Profit Margin33.67%
Debt/Equity Ratio30.7%

How did SELB perform over the long term?

See historical performance and comparison